Prevalence of reported knee pain over twelve years in a community‐based cohort

Abstract

Objective. To describe the temporal patterns of knee pain in a community-based cohort over 12 years.Methods. Data on self-reported knee pain at 4 time points over 12 years were analyzed in participants from the Chingford Women's Study of osteoarthritis (OA) and osteoporosis. Pain status was defined as any pain in the preceding month and pain on most days in the preceding month. This status was used to classify participants according to pain patterns of asymptomatic, persistent, incident, or intermittent pain. Multinomial logistic regression was used to identify baseline predictors for each pain pattern.Results. Among the 489 women with complete followup data, the median age at baseline was 52 years (interquartile range [IQR] 48-58 years), the median body mass index (BMI) was 24.39 kg/m 2 (IQR 22.46-27.20), and 11.7% of the women had a Kellgren/ Lawrence radiographic OA severity grade of >2 in at least one knee. Among subjects reporting any pain in the preceding month versus those reporting pain on most days in the preceding month, 9% versus 2% had persistent pain, 24% versus 16% had incident pain, and 29% versus 18% had intermittent pain. A higher BMI was predictive of persistent pain (odds ratio [OR] 1.14, 95% confidence interval [95% CI] 1.04-1.25) and incident pain (OR 1.10, 95% CI 1.02-1.18). The presence of radiographic knee OA was predictive of persistent pain (OR 3.70, 95% CI 1.34-10.28; P ‫؍‬ 0.012), and reported knee injury was predictive of both persistent pain (OR 4.13, 95% CI 1.34-12.66; P ‫؍‬ 0.013) and intermittent pain (OR 4.25, 95% CI 1.81-9.98; P ‫؍‬ 0.001).Conclusion. Significant variability in the temporal fluctuation of self-reported knee pain was seen in this community-based prospective study over a period of 12 years, with few women consistently reporting knee pain at each time point. Distinct baseline predictors for each pain pattern were identified and may explain the observed heterogeneity of self-reported knee pain when pain status is measured at only one time point.

Painful knee but not hand osteoarthritis is an independent predictor of mortality over 23 years follow-up of a population-based cohort of middle-aged women

“…PA is also an important mediator of this inflammatory response42 and inactivity linked with painful KOA might accelerated metabolic dysregulation 43 44. The pain in KOA fluctuates28 and people commonly limit the activities associated with their symptoms and perceive PA to lead to the disease progression 45 46. Despite, clear evidence suggesting that PA improves pain, quality of life and minimises disability in individuals with KOA,47 we lack evidence supporting that any interventions in patients with KOA improve PA levels or cardiovascular fitness in the longer term 48 49…”

“…Knee and hand pain was assessed at year 3 as part of a self-administered questionnaire 28. Women were asked if they had experienced any knee/hand pain in the past month and the number of days this had occurred.…”

5th International Workshop on Advances in the Molecular Pharmacology and Therapeutics of Bone Disease: Oxford Workshop 2012

“…25,26 The potential for strontium ranelate as a therapy in this setting was also explored based on emerging evidence from phase III trials, suggesting a decreased progression of vertebral OA and up to 30 % decrease in knee joint space narrowing following treatment with strontium ranelate. The continuing search for better therapies to treat inflammatory arthritic disease was discussed by Peter Taylor (Oxford) who clearly illustrated this need by emphasizing how only 20 % of patients on current anti-inflammatory drugs (for example, golimumab) show a good response.…”

Evaluating the Effectiveness of Phonophoresis by Piroxicam and Dimethyl Sulfoxide for Women’s With Osteoarthritis Knee Joint

“…There is no evidence that DMSO can alter progression of degenerative disease, and clinical trials are still lacking on the use of DMSO along with thermal modalities in the management of OA knee joint pain. Piroxicam is an NSAID used in musculoskeletal and joint disorders; piroxicam is more formulated in pharmaceutical industries because of their oil-free and water-removable desirability, efficacy, and harmless dermal effects [6].…”